Robert Gibbons to Central Nervous System Stimulants
This is a "connection" page, showing publications Robert Gibbons has written about Central Nervous System Stimulants.
Connection Strength
1.118
-
Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry. 2012 Feb; 169(2):167-77.
Score: 0.329
-
Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Suicide Attempts. Biol Psychiatry. 2020 09 15; 88(6):452-458.
Score: 0.142
-
Attention-Deficit/Hyperactivity Disorder Medication and Unintentional Injuries in Children and Adolescents. J Am Acad Child Adolesc Psychiatry. 2020 08; 59(8):944-951.
Score: 0.138
-
ADHD Medication and Substance-Related Problems. Am J Psychiatry. 2017 09 01; 174(9):877-885.
Score: 0.120
-
Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes. JAMA Psychiatry. 2017 06 01; 74(6):597-603.
Score: 0.119
-
Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013 Mar; 52(3):250-63.
Score: 0.088
-
3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007 Aug; 46(8):989-1002.
Score: 0.060
-
Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry. 2007 Aug; 46(8):1003-1014.
Score: 0.060
-
Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007 Aug; 46(8):1015-1027.
Score: 0.060